Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rosiglitazone(BRL-49653)].

N Yonezawa1, Y Oka

  • 1Third Department of Internal Medicine, Yamaguchi University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing parosmia patients: a study on the evaluation method using a self-administered odor questionnaire for parosmia.

Rhinology·2024
Same author

Disulfide linkage patterns of pig zona pellucida glycoproteins ZP3 and ZP4.

Molecular reproduction and development·2007
Same author

Structural significance of N-glycans of the zona pellucida on species-selective recognition of spermatozoa between pig and cattle.

Society of Reproduction and Fertility supplement·2007
Same author

Participation of the nonreducing terminal beta-galactosyl residues of the neutral N-linked carbohydrate chains of porcine zona pellucida glycoproteins in sperm-egg binding.

Molecular reproduction and development·2004
Same author

Molecular cloning of bovine zona pellucida glycoproteins ZPA and ZPB and analysis for sperm-binding component of the zona.

European journal of biochemistry·2001
Same author

Essential role of the nonreducing terminal alpha-mannosyl residues of the N-linked carbohydrate chain of bovine zona pellucida glycoproteins in sperm-egg binding.

Molecular reproduction and development·2001
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Rosiglitazone, an oral antidiabetic drug, effectively lowers blood glucose and insulin resistance by activating PPAR-gamma. Clinical studies show significant HbA1c improvements in type 2 diabetes patients, though liver function monitoring is advised.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Rosiglitazone (RSG) is an oral antidiabetic medication belonging to the thiazolidinedione (TDZ) class.
  • TDZs are believed to exert their antihyperglycemic effects by activating the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma).

Purpose of the Study:

  • To evaluate the efficacy and mechanism of action of Rosiglitazone in managing type 2 diabetes mellitus.
  • To compare the binding affinity of Rosiglitazone to PPAR-gamma with other thiazolidinediones.

Main Methods:

  • In vitro assessment of binding affinity to PPAR-gamma.
  • In vivo studies using animal models of insulin resistance.
  • Clinical trials involving type 2 diabetes patients, with and without combination therapy.

Related Experiment Videos

Main Results:

  • Rosiglitazone demonstrated a higher affinity for PPAR-gamma compared to troglitazone and pioglitazone.
  • In animal models, RSG reduced plasma glucose, triglycerides, and insulin levels, and prevented diabetic complications.
  • Clinical studies showed significant improvements in HbA1c levels when RSG was used alone or with metformin or sulfonylurea.

Conclusions:

  • Rosiglitazone is a potent activator of PPAR-gamma, correlating with its in vivo antidiabetic efficacy.
  • RSG effectively improves glycemic control in type 2 diabetes mellitus patients.
  • Close monitoring of liver function is recommended for patients undergoing Rosiglitazone treatment.